# Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD

> **NCT02321241** · — · COMPLETED · sponsor: **Bayer** · enrollment: 236 (actual)

## Conditions studied

- Wet Macular Degeneration

## Interventions

- **DRUG:** Aflibercept (EYLEA, BAY-86-5321)

## Key facts

- **NCT ID:** NCT02321241
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-01
- **Primary completion:** 2017-01-18
- **Final completion:** 2017-08-18
- **Target enrollment:** 236 (ACTUAL)
- **Last updated:** 2018-07-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02321241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02321241, "Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02321241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*